Evidence map›Paper›PMID 34776222›Full record

ArticleMethods in enzymology2021

An efficient chemical screening method for structure-based inhibitors to nucleic acid enzymes targeting the DNA repair-replication interface and SARS CoV-2.

Davide Moiani, Todd M Link, Chris A Brosey, Panagiotis Katsonis, Olivier Lichtarge, Youngchang Kim, Andrzej Joachimiak, Zhijun Ma, In-Kwon Kim, Zamal Ahmed and 3 more

Open access · greenAbstract read
In one paragraph

Article in Methods in enzymology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
3.7field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 6 institutions in 1 country.

Davide MoianiDepartment of Cancer Biology, University of Texas MD Anderson Cancer Center, Houston, TX, United States; Department of Molecular & Cellular Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, United States.
Todd M LinkDepartment of Cancer Biology, University of Texas MD Anderson Cancer Center, Houston, TX, United States; Department of Molecular & Cellular Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, United States.
Chris A BroseyDepartment of Cancer Biology, University of Texas MD Anderson Cancer Center, Houston, TX, United States; Department of Molecular & Cellular Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, United States.
Panagiotis KatsonisDepartment of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX, United States.
Olivier LichtargeDepartment of Molecular and Human Genetics, Baylor College of Medicine, Houston, TX, United States.
Youngchang KimCenter for Structural Genomics of Infectious Diseases, Consortium for Advanced Science and Engineering, University of Chicago, Chicago, IL, United States; Department of Biochemistry and Molecular Biology, University of Chicago, Chicago, IL, United States.
Andrzej JoachimiakCenter for Structural Genomics of Infectious Diseases, Consortium for Advanced Science and Engineering, University of Chicago, Chicago, IL, United States; Department of Biochemistry and Molecular Biology, University of Chicago, Chicago, IL, United States.
Zhijun MaDepartment of Chemistry, University of Cincinnati, Cincinnati, OH, United States.
In-Kwon KimDepartment of Chemistry, University of Cincinnati, Cincinnati, OH, United States.
Zamal AhmedDepartment of Cancer Biology, University of Texas MD Anderson Cancer Center, Houston, TX, United States; Department of Molecular & Cellular Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, United States.
Darin E JonesDepartment of Pharmaceutical Sciences, The University of Arkansas for Medical Sciences, Little Rock, AR, United States.
Susan E TsutakawaBiophysics and Integrated Bioimaging, Lawrence Berkeley National Laboratory, Berkeley, CA, United States. Electronic address: setsutakawa@lbl.gov.
John A TainerDepartment of Cancer Biology, University of Texas MD Anderson Cancer Center, Houston, TX, United States; Department of Molecular & Cellular Oncology, University of Texas MD Anderson Cancer Center, Houston, TX, United States; Biophysics and Integrated Bioimaging, Lawrence Berkeley National Laboratory, Berkeley, CA, United States. Electronic address: jtainer@mdanderson.org.
The University of Texas MD Anderson Cancer Center · USBaylor College of Medicine · USLawrence Berkeley National Laboratory · USUniversity of Chicago · USUniversity of Cincinnati · USUniversity of Arkansas for Medical Sciences · US

Funding

Transcription-Coupled & Replication-Associated Excision RepairP01CA092584 · NCI · UNIVERSITY OF CALIF-LAWRENC BERKELEY LAB · PI John A. Tainer · 2001 to 2026
$89.6M
User Training and OutreachP30GM124169 · NIGMS · UNIVERSITY OF CALIF-LAWRENC BERKELEY LAB · PI Gregory L Hura · 2017 to 2026
$28.6M
Mesoscale and Nanoscale Technologies Integrated by Structures for DNA Repair Complexes (MANTIS-DRC)R35CA220430 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI John A. Tainer · 2018 to 2026
$7.6M
Eliminating Critical Systematic Errors In Structural Biology With Next-Generation SimulationR01GM124149 · NIGMS · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI HOLTON, JAMES M · 2017 to 2024
$2.5M
Reversal of residue-specific ADP-ribosylations by ADP-ribosyl-acceptor hydrolasesR01GM141226 · NIGMS · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI KIM, IN-KWON · 2021 to 2024
$1.4M
NCI NIH HHS P01 CA092584NCI NIH HHS R35 CA220430NIGMS NIH HHS P30 GM124169NIGMS NIH HHS R01 GM124149NIGMS NIH HHS R01 GM141226
6 · The paper itself

Abstract

We present a Chemistry and Structure Screen Integrated Efficiently (CASSIE) approach (named for Greek prophet Cassandra) to design inhibitors for cancer biology and pathogenesis. CASSIE provides an effective path to target master keys to control the repair-replication interface for cancer cells and SARS CoV-2 pathogenesis as exemplified here by specific targeting of Poly(ADP-ribose) glycohydrolase (PARG) and ADP-ribose glycohydrolase ARH3 macrodomains plus SARS CoV-2 nonstructural protein 3 (Nsp3) Macrodomain 1 (Mac1) and Nsp15 nuclease. As opposed to the classical massive effort employing libraries with large numbers of compounds against single proteins, we make inhibitor design for multiple targets efficient. Our compact, chemically diverse, 5000 compound Goldilocks (GL) library has an intermediate number of compounds sized between fragments and drugs with predicted favorable ADME (absorption, distribution, metabolism, and excretion) and toxicological profiles. Amalgamating our core GL library with an approved drug (AD) library, we employ a combined GLAD library virtual screen, enabling an effective and efficient design cycle of ranked computer docking, top hit biophysical and cell validations, and defined bound structures using human proteins or their avatars. As new drug design is increasingly pathway directed as well as molecular and mechanism based, our CASSIE approach facilitates testing multiple related targets by efficiently turning a set of interacting drug discovery problems into a tractable medicinal chemistry engineering problem of optimizing affinity and ADME properties based upon early co-crystal structures. Optimization efforts are made efficient by a computationally-focused iterative chemistry and structure screen. Thus, we herein describe and apply CASSIE to define prototypic, specific inhibitors for PARG vs distinct inhibitors for the related macrodomains of ARH3 and SARS CoV-2 Nsp3 plus the SARS CoV-2 Nsp15 RNA nuclease.

Indexed as

COVID-19Nucleic AcidsSevere Acute Respiratory SyndromeDNA RepairHumansMolecular Docking SimulationSARS-CoV-2Nucleic AcidsCancerChemical libraryDNA replication and repairDrug discoverySars-COV2

Identifiers

PMID34776222
PMCPMC8474023
OpenAlexW3204517494

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.